Evidence map›Paper›PMID 33800399›Full record

ArticleMolecules (Basel, Switzerland)2021

Insight into Functional Membrane Proteins by Solution NMR: The Human Bcl-2 Protein-A Promising Cancer Drug Target.

Ameeq Ul Mushtaq, Jörgen Ådén, Tobias Sparrman, Mattias Hedenström, Gerhard Gröbner

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ameeq Ul MushtaqDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.
Jörgen ÅdénDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0000-0002-4480-1219
Tobias SparrmanDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.
Mattias HedenströmDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0000-0002-0903-6662
Gerhard GröbnerDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0000-0001-7380-8797
Umeå University · SE

Funding

Cancerfonden CAN 2015/482Knut och Alice Wallenbergs Stiftelse NMRforLIfeVetenskapsrådet 2016-06963
6 · The paper itself

Abstract

Evasion from programmed cell death (apoptosis) is the main hallmark of cancer and a major cause of resistance to therapy. Many tumors simply ensure survival by over-expressing the cell-protecting (anti-apoptotic) Bcl-2 membrane protein involved in apoptotic regulation. However, the molecular mechanism by which Bcl-2 protein in its mitochondrial outer membrane location protects cells remains elusive due to the absence of structural insight; and current strategies to therapeutically interfere with these Bcl-2 sensitive cancers are limited. Here, we present an NMR-based approach to enable structural insight into Bcl-2 function; an approach also ideal as a fragment-based drug discovery platform for further identification and development of promising molecular Bcl-2 inhibitors. By using solution NMR spectroscopy on fully functional intact human Bcl-2 protein in a membrane-mimicking micellar environment, and constructs with specific functions remaining, we present a strategy for structure determination and specific drug screening of functional subunits of the Bcl-2 protein as targets. Using

Indexed as

Antineoplastic AgentsApoptosisApoptosis Regulatory ProteinsDrug DiscoveryDrug Evaluation, PreclinicalHumansMagnetic Resonance SpectroscopyMembrane ProteinsMitochondriaMitochondrial MembranesModels, MolecularNeoplasmsProtein BindingProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsApoptosis Regulatory ProteinsBCL2 protein, humanMembrane ProteinsProto-Oncogene Proteins c-bcl-2Bcl-2 membrane proteindrug screeningNMR

Identifiers

PMID33800399
PMCPMC7962812
OpenAlexW3133837920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.